SCHEMBL6472256

SCHEMBL6472256

CCOC(=O)/C=C/c1ccc(OC)c(-c2cc3c(cc2OCc2ccccc2)C(C)(C)CCC3(C)C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.51
CA12 O43570 1/20 0.51
CA4 P22748 1/20 0.51
CA6 P23280 1/20 0.51
CA5A P35218 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
CA14 Q9ULX7 1/20 0.51
CA5B Q9Y2D0 1/20 0.51
APP P05067 7/20 0.50
KDM4E B2RXH2 3/20 0.49
LMNA P02545 1/20 0.49
TTR P02766 2/20 0.48
MAOB P27338 1/20 0.47
HPGD P15428 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HTT P42858 1/20 0.47
MMP1 P03956 3/20 0.47
MMP2 P08253 2/20 0.47
MMP3 P08254 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6472257 1.00 FDPS (0.51) FDPSCA12CA4CA6CA5A
SCHEMBL6477944 0.94 FDPS (0.50) FDPSCA12CA4CA6CA5A
SCHEMBL6477948 0.94 FDPS (0.50) FDPSCA12CA4CA6CA5A
SCHEMBL6472405 0.92 KDM4E (0.47) FDPSCA12CA4CA6CA5A
SCHEMBL6472400 0.92 KDM4E (0.47) FDPSCA12CA4CA6CA5A
SCHEMBL6472933 0.92 CA12 (0.49) FDPSCA12CA4CA6CA5A
SCHEMBL6472928 0.92 CA12 (0.49) FDPSCA12CA4CA6CA5A
SCHEMBL6477344 0.91 FDPS (0.48) FDPSCA12CA4CA6CA5A
SCHEMBL6477343 0.91 FDPS (0.48) FDPSCA12CA4CA6CA5A
SCHEMBL6479475 0.91 RXRA (0.55) FDPSCA12CA4CA6CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US claimed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US claimed
EP-0947496-B1 Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology GALDERMA RES & DEV (FR) 2002-10-09 EP claimed
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R FDPS 3696/4885CA12 4307/4885CA4 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.